Management Team

Ophthotech has assembled a team with proven experience in research, clinical development and commercialization of novel therapies for diseases of the eye.

David Guyer

David R. Guyer, M.D.

Chief Executive Officer

David Guyer, M.D. is a Co-Founder and Chief Executive Officer of Ophthotech Corporation and also serves as Chairman of its board of directors. Dr. Guyer previously worked as a venture capitalist and Partner at SV Life Sciences. He has significant medical, drug development and commercial experience in ophthalmology.

Following a successful career in academic medicine as Professor and Chairman of the Department of Ophthalmology at New York University School of Medicine, Dr. Guyer co-founded and served as CEO and Director at Eyetech Pharmaceuticals, Inc., where he led the company through private, public and corporate financings over $400 million, and oversaw the rapid development and successful commercialization of Macugen® (pegaptanib sodium), the first FDA-approved anti-VEGF pharmacological treatment for wet AMD. Under his leadership, Eyetech reached a peak market capitalization of approximately $2 billion.

Dr. Guyer received his Bachelor of Science (B.S.) degree from Yale College summa cum laude and his medical degree (M.D.) from Johns Hopkins Medical School. He completed his ophthalmology residency at Wilmer Ophthalmological Institute at Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.

Glenn Sblendorio

Glenn P. Sblendorio, M.B.A.

President and Chief Financial Officer

Glenn Sblendorio, M.B.A., is President and Chief Financial Officer of Ophthotech Corporation. He joined Ophthotech in 2016 as Executive Vice President, Chief Operating Officer and Chief Financial Officer. He also served as a member of the Board of Directors of Ophthotech from 2013 to 2016. Prior to joining Ophthotech, he served as President and Chief Financial Officer and member of the Board of Directors of The Medicines Company from 2006 to 2016. Mr. Sblendorio served as Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from 2002 through 2005 when it was sold to OSI Pharmaceuticals. From 2000 through 2002, he held the title of Senior Vice President of Business Development for The Medicines Company. His pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc. in a variety of senior financial positions. Mr. Sblendorio currently serves on the Board of Directors of Amicus Therapeutics and Intercept Pharmaceuticals. Mr. Sblendorio received his Bachelor of Business Administration degree from Pace University and a Master of Business Administration degree from Fairleigh Dickinson University, and he is a graduate of the Harvard Business School Advanced Management Program.

Carmen A. Puliafito, M.D., M.B.A.

Chief of Strategic Development

As one of the world’s leading experts in ophthalmology and health management, Dr. Puliafito’s highly distinguished career includes serving most recently as the Dean of the Keck School of Medicine of the University of Southern California, a position that he held from 2007 to 2016. Under his leadership, the Keck School of Medicine has become one of the nation’s preeminent research-intensive medical schools. Prior to that, Dr. Puliafito served as Chair and Professor of the Department of Ophthalmology at the Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine, a leading eye center in the world. Prior to his leadership at Bascom Palmer, he served as founding director of the New England Eye Center and Chair and Professor of the Department of Ophthalmology at Tufts University.

Dr. Puliafito is recognized worldwide for his innovative advances such as the co-invention of optical coherence tomography (OCT), a revolutionary technology for the management of macular diseases. He also pioneered basic science research in excimer laser photoablation and optical breakdown and photodisruption. Dr. Puliafito has also been at the forefront of clinical innovation, including the introduction of Avastin® for the treatment of retinal disorders. Dr. Puliafito is on leave from his position as Professor of Ophthalmology and Health Management at the USC Roski Eye Institute.

Dr. Puliafito received his medical degree (M.D.) from Harvard Medical School and a Master of Business Administration (M.B.A.) degree from the Wharton School of the University of Pennsylvania.

Henric Bjarke

Henric Bjarke

Senior Vice President and Chief Commercial Officer

Mr. Bjarke serves as Senior Vice President and Chief Commercial Officer of Ophthotech Corporation. Prior to joining Ophthotech, he was with Alexion, where he successfully managed commercial operations in the U.S. and Canada, launching their lead product Soliris® for aHUS while expanding the efforts for the PNH indication. Most recently, he was responsible for building the global commercial and operations infrastructure to support the commercialization efforts for Alexion’s metabolic disease portfolio.

Mr. Bjarke brings a wealth of commercial experience in the retina and ophthalmology market, having previously served as Vice President of Sales and Marketing at Eyetech Pharmaceuticals and playing an important role in bringing the first anti-VEGF product to market for the treatment of wet AMD. In addition, Mr. Bjarke held several roles with increased responsibilities at Pharmacia and Watson Pharmaceuticals. He managed multiple U.S. and global brands and successfully managed several major launches including XALATAN®, which was the world’s number one brand of glaucoma medication (based on market share) and the first ophthalmic medicine to achieve blockbuster status.

Mr. Bjarke holds a Bachelor of Applied Science (B.A. Sc.) degree in Business Administration and Economics from Uppsala University, Sweden.

Evelyn Harrison

Evelyn Harrison, M.B.A.

Chief Clinical Operations Officer

Evelyn Harrison, M.B.A., is the Chief Clinical Operations Officer of Ophthotech Corporation. She brings more than 23 years of management and clinical research experience.

Prior to joining Ophthotech, Ms. Harrison was with Eyetech Pharmaceuticals, Inc., where she held the management positions of Vice President and Senior Vice President of Clinical Research and Development. During her stint at this company, she played a key role in the development and approval of Macugen® (pegaptanib sodium) for the treatment of wet age-related macular degeneration.

Ms. Harrison’s professional career began in clinical research at a major New York City teaching hospital. She then moved to Hoffmann-La Roche Inc., where she was Director of Clinical Operations, responsible for the development and implementation of strategic programs for Roche’s oncology franchise.

Ms. Harrison has worked on all phases of global clinical trials and has extensive experience in multiple therapeutic areas such as bone marrow transplantation, organ transplantation, oncology and virology.

Ms. Harrison holds a B.A. degree in Biology from Hofstra University and a Master of Business Administration (M.B.A.) degree from Manhattan College.

Kourous A. Rezaei, M.D.

Kourous A. Rezaei, M.D.

Senior Vice President, Medical Strategy

Dr. Rezaei serves as the Senior Vice President, Medical Strategy of Ophthotech Corporation. He is a board certified ophthalmologist that specializes in the medical and surgical treatment of vitreoretinal diseases, and has been recognized with multiple awards in the ophthalmology space, including the Beem Fisher Award from the Chicago Ophthalmological Society and the American Academy of Ophthalmology Achievement Award. Dr. Rezaei had served on the Editorial Board of the journal of Investigative Ophthalmology & Visual Science (IOVS) and currently is a voting member on the Board of Directors of the American Society of Retina Specialists (ASRS). He has authored over 30 articles, five medical textbook chapters, and has presented over 80 abstracts in 26 countries. Dr. Rezaei is an Associate Professor of Ophthalmology and the Director of the Vitreoretinal Fellowship Program at Rush University Medical Center and is a senior partner at Illinois Retina Associates in Chicago. Previously, he was the Director of Vitreoretinal Service at the University of Chicago. Dr. Rezaei also founded “ChannelR”, a digital media education program for retina specialists.

Dr. Rezaei received his medical degree from the University of Cologne in Germany. He served as chief resident while completing his residency at the University of Chicago. Dr. Rezaei completed his vitreoretinal surgery fellowship at the Kresge Eye Institute in Detroit.

Dr. Thomas A. Ciulla, M.D., M.B.A.

Thomas A. Ciulla, M.D., M.B.A.

Vice President, Clinical Strategy

Thomas Ciulla, M.D. is the Vice President, Clinical Strategy of Ophthotech Corporation. Dr. Ciulla graduated from Harvard College and the University of California San Francisco UCSF School of Medicine, followed by internship and ophthalmology residency at Harvard Medical School, and then a retina fellowship at Tufts Medical School. He was Co-Director of the Retina Service and Retina Research laboratory at Indiana University School of Medicine, served on the board of directors of a large multi-subspecialty ophthalmology group, and remains a volunteer Clinical Professor of Ophthalmology. He has played numerous roles in over 100 national clinical trials, including principal investigator, medical monitor, or member of scientific advisory, data safety monitoring or writing committees. He has co-authored over 100 Medline indexed papers, and is an active member of the Macula and Retina Societies, American Society of Retina Specialists, American Academy of Ophthalmology and The Association for Research in Vision and Ophthalmology. Prior to joining the Ophthotech team, he earned an MBA from Indiana University’s Kelley School of Business, specializing in the business of medicine.
Dan Salain

Dan Salain

Senior Vice President, Technical Operations

Mr. Salain brings over 25 years of global pharmaceutical experience in Manufacturing, Supply Chain, Strategic Sourcing, Distribution, Quality, Operations and Business Development. Over the past 25 years Dan has participated in the successful launch and introduction of over 30 products globally including Zenpep, Lamictal, Amrix, Canasa, and Metadate CD. Most recently Dan was Vice President, Global Supply Chain and Manufacturing at Aptalis Pharma where he built a supply chain team and managed manufacturing sites in Italy, France, Canada and the US. Prior to joining Aptalis Dan was the Vice President of Operations at Eurand where he lead several technology and licensing deals in addition to running the Operations team. He earned a Bachelor of Science degree in chemistry from the University of Indianapolis.
Keith Westby

Keith Westby, M.B.A.

Senior Vice President and Chief Operating Officer

Keith Westby is Senior Vice President and Chief Operating Officer of Ophthotech Corporation. Westby joined Ophthotech in 2007 and has more than fifteen years of experience in program and strategic alliance management and manufacturing operations in biotechnology companies. Mr. Westby was most recently Senior Vice President, Development Operations of Ophthotech. Prior to joining Ophthotech, Mr. Westby worked at Pharmasset, Inc., as Director, Project and Alliance Management. He also served in positions of increasing responsibility at Eyetech Pharmaceuticals, including Director, Alliance & Project Management, leading multifunctional project teams in the New Drug Application filing and marketing approval of Macugen® (a pegylated oligonucleotide). Previously, Mr. Westby worked at Tunnell Consulting, where he was a Senior Consultant in the firm’s Life Sciences practice focused on manufacturing operations and process improvement. Mr. Westby holds a Bachelor of Science degree in Applied Physics from the State University of New York, College at Geneseo, a Master of Science degree in Engineering Management from Drexel University, and a Master of Business Administration degree from Columbia Business School.

Barbara Wood

Senior Vice President and General Counsel

Barbara Wood is Senior Vice President and General Counsel of Ophthotech Corporation. Ms. Wood has been practicing law for more than 25 years. Prior to joining Ophthotech, she was Senior Vice President and General Counsel at OSI Pharmaceuticals, Inc., where she played a significant role in the integration and transition process when Astellas Pharma acquired OSI in 2010.

Before joining OSI, Ms. Wood was a partner at the New York firm of Squadron, Ellenoff, Plesent & Sheinfeld (now part of Hogan Lovells), focusing on mergers and acquisitions, biotechnology, licensing, securities and venture capital matters. While at Squadron Ellenoff, she also worked on transactions for some of the earliest biotech companies, representing an early biotech venture capitalist and angel investor. Ms. Wood received her law degree from Columbia Law School and has a Bachelor of Arts (B.A.) degree in Economics and Classics from Connecticut College.